Georges Gemayel Sells 10,000 Shares of Supernus Pharmaceuticals (NASDAQ:SUPN) Stock

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Director Georges Gemayel sold 10,000 shares of the firm’s stock in a transaction dated Thursday, March 5th. The stock was sold at an average price of $53.71, for a total transaction of $537,100.00. Following the transaction, the director directly owned 28,159 shares of the company’s stock, valued at $1,512,419.89. The trade was a 26.21% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Georges Gemayel also recently made the following trade(s):

• On Friday, March 6th, Georges Gemayel sold 8,787 shares of Supernus Pharmaceuticals stock. The shares were sold at an average price of $53.00, for a total transaction of $465,711.00.

Supernus Pharmaceuticals Stock Down 0.9%

NASDAQ:SUPN opened at $53.67 on Wednesday. Supernus Pharmaceuticals, Inc. has a 12-month low of $29.16 and a 12-month high of $59.68. The firm has a market capitalization of $3.09 billion, a PE ratio of -78.93, a price-to-earnings-growth ratio of 1.68 and a beta of 0.70. The firm has a 50-day moving average price of $51.12 and a 200 day moving average price of $48.96.

Wall Street Analysts Forecast Growth

SUPN has been the topic of several recent analyst reports. Zacks Research lowered Supernus Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research note on Thursday, January 29th. Stifel Nicolaus increased their price objective on Supernus Pharmaceuticals from $50.00 to $55.00 and gave the stock a “hold” rating in a research note on Friday, December 19th. Craig Hallum set a $65.00 price objective on Supernus Pharmaceuticals in a report on Wednesday, February 25th. Wall Street Zen downgraded shares of Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Sunday. Finally, Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a report on Monday, December 29th. Four equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $62.17.

Institutional Investors Weigh In On Supernus Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Commonwealth of Pennsylvania Public School Empls Retrmt SYS increased its stake in shares of Supernus Pharmaceuticals by 8.8% in the second quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 14,375 shares of the specialty pharmaceutical company’s stock valued at $453,000 after buying an additional 1,161 shares in the last quarter. Universal Beteiligungs und Servicegesellschaft mbH lifted its position in Supernus Pharmaceuticals by 30.4% during the 2nd quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 85,534 shares of the specialty pharmaceutical company’s stock worth $2,696,000 after buying an additional 19,949 shares in the last quarter. Ruffer LLP acquired a new position in Supernus Pharmaceuticals during the 3rd quarter worth about $2,647,000. Systematic Financial Management LP grew its holdings in Supernus Pharmaceuticals by 47.5% during the 2nd quarter. Systematic Financial Management LP now owns 245,545 shares of the specialty pharmaceutical company’s stock worth $7,740,000 after acquiring an additional 79,041 shares during the last quarter. Finally, XTX Topco Ltd bought a new stake in Supernus Pharmaceuticals during the 2nd quarter worth about $1,301,000.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.